Overview

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Status:
Terminated

Trial end date:
2018-02-19

Target enrollment:

Participant gender:

Summary

This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Kuhnil Pharmaceutical Co., Ltd.

Collaborator:

Daiichi Sankyo Co., Ltd.

Treatments:

Camptothecin
Irinotecan
Nimotuzumab